Changes in Metabolic Status in Patients With Total Thyroidectomy

Thyroid Cancer Clinical Trial

— Thyroid cancer  

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01781767
• Other study ID #: TASMC-12-NV-376-CTIL
• Status: Recruiting
• Phase: N/A
• First received: January 27, 2013
• Last updated: January 30, 2013
• Start date: January 2013
• Est. completion date: July 2014

Study information

• Verified date: January 2013
• Source: Tel-Aviv Sourasky Medical Center
• Contact: Nachum Vaisman, M.D.
• Phone: 972-3-6974807
• Email: vaisman[@]tasmc.health.gov.il
• Is FDA regulated: No
• Health authority: Israel: Ministry of Health
• Study type: Observational

Clinical Trial Summary

This study objective is to evaluate the change in mitochondrial uncoupling protein 2 (UCP2) mRNA expression as function of thyroid activity (TSH, T3 and Free T4).

Description:

Blood will be drown before thyroidectomy, 2 weeks after the operation and 3-4 month after the operation.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: July 2014
• Est. primary completion date: July 2014
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Patients who were diagnosed with thyroid carcinoma and are going to have total thyroidectomy.

• Patients with unbalanced thyroid hormones.

• Aged 18-65 years at the time of screening.

• Provision of written informed consent.

Exclusion Criteria:

• Patients with Diabetes.

• Patients with any other chronic inflammatory diseases.

• Steroid treatment.

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

• Thyroid Cancer
• Thyroid Neoplasms

Locations

Country	Name	City	State
Israel	Tel Aviv Sourasky Medical Center	Tel Aviv

Sponsors (1)

Lead Sponsor	Collaborator
Tel-Aviv Sourasky Medical Center

Country where clinical trial is conducted

Israel, 

References & Publications (5)

Brand MD, Esteves TC. Physiological functions of the mitochondrial uncoupling proteins UCP2 and UCP3. Cell Metab. 2005 Aug;2(2):85-93. Review. — View Citation

Gjedde S, Gormsen LC, Riis AL, Jørgensen JO, Rungby J, Møller N, Weeke J, Pedersen SB. Reduced expression of uncoupling protein 2 in adipose tissue in patients with hypothyroidism. J Clin Endocrinol Metab. 2010 Jul;95(7):3537-41. doi: 10.1210/jc.2009-0907. Epub 2010 Apr 28. — View Citation

Nicholls DG, Locke RM. Thermogenic mechanisms in brown fat. Physiol Rev. 1984 Jan;64(1):1-64. Review. — View Citation

Schwartz HL, Oppenheimer JH. Physiologic and biochemical actions of thyroid hormone. Pharmacol Ther B. 1978;3(3):349-76. Review. — View Citation

Yen PM. Physiological and molecular basis of thyroid hormone action. Physiol Rev. 2001 Jul;81(3):1097-142. Review. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in UCP2 mRNA concentrations.	The difference between the result at two weeks and four months compare to base line.	Base line (before opporation), 2 weeks after opporation and for after opporation.	No
Secondary	Weight		Approximately 4 months	No
Secondary	Resting energy expenditure		Approximatly 4 months	No